As mentioned before, the combination treatment of afatinib and MET inhibitor AMG 337 resulted in complete tumor response in a xenograft model with one post-afatinib, MET amplified progression site from one gastric cancer patient [30]. The gene discussed is MET; the disease is gastric cancer.